Literature DB >> 29203416

Quantitative contributions of processes by which polyanion drugs reduce intracellular bioavailability and transfection efficiency of cationic siRNA lipoplex.

Pharavee Jaiprasart1, Bertrand Z Yeung2, Ze Lu3, M Guillaume Wientjes3, Minjian Cui4, Chien-Ming Hsieh5, Sukyung Woo1, Jessie L-S Au6.   

Abstract

RNA Interference (RNAi) is a potentially useful tool to correct the detrimental effects of faulty genes; several RNAi are undergoing clinical evaluation in various diseases. The present study identified the relative contributions of three mechanisms by which polyanion drugs reduced the gene silencing activity of Lipoplex, a complex of small interfering RNA (siRNA) and cationic liposomes. The study used a siRNA against the chemoresistance gene survivin and two model polyanion drugs (suramin, heparin). Products of Lipoplex destabilization were separated, identified, and/or quantified using ultrafiltration, gel electrophoresis, and RT-qPCR (quantitative reverse transcription polymerase chain reaction). Cell binding and endocytosis of fluorescence-labeled Lipoplex and the amount of siRNA at its site of action RISC (RNA-induced silencing complex) were evaluated using endocytosis markers, confocal microscopy, quantitative image analysis, immunoprecipitation, and RT-qPCR. The results show suramin and heparin exerted multiple concentration-dependent effects. First, these agents altered several Lipoplex properties (i.e., reduced particle size, changed surface charge, modified composition of protein biocorona). Second, both caused Lipoplex destabilization to release double- and single-strand siRNA and/or smaller siRNA-lipid complexes with reduced siRNA cargo. Third, both prevented the cell surface binding and internalization of Lipoplex, diminished the siRNA concentration in RISC, and retarded the mRNA knockdown. Suramin and heparin yielded qualitatively and quantitatively different results. Analysis of the experimental results of suramin using quantitative pharmacology (QP) modeling indicated the major cause of gene silencing activity loss depended on drug concentration, changing from inhibition of endocytosis at lower concentration (accounting for 60% loss at ~9μM) to inhibition of cell surface binding and loss of siRNA cargo at higher concentrations (accounting for 64% and 27%, respectively, at 70μM). In summary, the present study demonstrates the complex and dynamic interactions between polyanions and Lipoplex, and the use of QP modeling to delineate the contributions of three mechanisms to the eventual loss of gene silencing activity.
Copyright © 2017 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Anionic drug; Binding; Biocorona; Destabilization; Internalization; siRNA lipoplex

Mesh:

Substances:

Year:  2017        PMID: 29203416      PMCID: PMC5808856          DOI: 10.1016/j.jconrel.2017.12.001

Source DB:  PubMed          Journal:  J Control Release        ISSN: 0168-3659            Impact factor:   9.776


  62 in total

Review 1.  Delivery of siRNA therapeutics: barriers and carriers.

Authors:  Jie Wang; Ze Lu; M Guillaume Wientjes; Jessie L-S Au
Journal:  AAPS J       Date:  2010-06-11       Impact factor: 4.009

2.  Nontoxic doses of suramin enhance activity of paclitaxel against lung metastases.

Authors:  S Song; M G Wientjes; C Walsh; J L Au
Journal:  Cancer Res       Date:  2001-08-15       Impact factor: 12.701

3.  Therapeutic silencing of an endogenous gene by systemic administration of modified siRNAs.

Authors:  Jürgen Soutschek; Akin Akinc; Birgit Bramlage; Klaus Charisse; Rainer Constien; Mary Donoghue; Sayda Elbashir; Anke Geick; Philipp Hadwiger; Jens Harborth; Matthias John; Venkitasamy Kesavan; Gary Lavine; Rajendra K Pandey; Timothy Racie; Kallanthottathil G Rajeev; Ingo Röhl; Ivanka Toudjarska; Gang Wang; Silvio Wuschko; David Bumcrot; Victor Koteliansky; Stefan Limmer; Muthiah Manoharan; Hans-Peter Vornlocher
Journal:  Nature       Date:  2004-11-11       Impact factor: 49.962

Review 4.  Cationic lipids: molecular structure/ transfection activity relationships and interactions with biomembranes.

Authors:  Rumiana Koynova; Boris Tenchov
Journal:  Top Curr Chem       Date:  2010

Review 5.  Surface charge: a key determinant of protein localization and function.

Authors:  Neil M Goldenberg; Benjamin E Steinberg
Journal:  Cancer Res       Date:  2010-02-02       Impact factor: 12.701

Review 6.  Heparan sulfate and heparin interactions with proteins.

Authors:  Maria C Z Meneghetti; Ashley J Hughes; Timothy R Rudd; Helena B Nader; Andrew K Powell; Edwin A Yates; Marcelo A Lima
Journal:  J R Soc Interface       Date:  2015-09-06       Impact factor: 4.118

Review 7.  Heparin-binding domains in vascular biology.

Authors:  Eva M Muñoz; Robert J Linhardt
Journal:  Arterioscler Thromb Vasc Biol       Date:  2004-07-01       Impact factor: 8.311

8.  Surface adsorption of protein corona controls the cell internalization mechanism of DC-Chol-DOPE/DNA lipoplexes in serum.

Authors:  Giulio Caracciolo; Luciano Callipo; Sofia Candeloro De Sanctis; Chiara Cavaliere; Daniela Pozzi; Aldo Laganà
Journal:  Biochim Biophys Acta       Date:  2009-11-14

9.  Suramin binds to platelet-derived growth factor and inhibits its biological activity.

Authors:  M Hosang
Journal:  J Cell Biochem       Date:  1985       Impact factor: 4.429

Review 10.  Current prospects for RNA interference-based therapies.

Authors:  Beverly L Davidson; Paul B McCray
Journal:  Nat Rev Genet       Date:  2011-05       Impact factor: 53.242

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.